Methadone Pediatric Dose — Analgesia
Methadone is a synthetic opioid analgesic that acts primarily as a mu-opioid receptor agonist with additional NMDA receptor antagonist properties. It is used in pediatric patients for moderate-to-severe pain management, opioid-sparing strategies, and opioid weaning protocols. Its long and unpredictable half-life distinguishes it from other opioids and necessitates careful individualized dosing.
Pediatric Dosing
Initial dose: 0.1 mg/kg/dose IV or PO every 6 hours.
- Route: Intravenous (IV) or oral (PO)
- Frequency: Every 6 hours (initial)
Worked example: For a 20 kg child: 20 × 0.1 mg/kg = 2 mg per dose IV or PO every 6 hours.
Important: Methadone conversion is highly variable depending on the purpose of its use. Please consult the pain service or pharmacy MED service for methadone dosing recommendations before initiating or converting to methadone therapy. Do not adjust doses without specialist input.
Indications and Clinical Context
Methadone is indicated in pediatric patients for management of moderate-to-severe pain, particularly in settings where prolonged analgesia or opioid rotation is required, such as oncologic pain, chronic pain syndromes, or PICU-based comfort care. It is also used as part of structured opioid weaning protocols for patients who have developed opioid tolerance or dependence following prolonged infusions.
Due to its complex pharmacokinetics—including a highly variable elimination half-life (ranging from hours to days), risk of QTc prolongation, and non-linear equianalgesic conversion ratios—methadone requires individualized dosing. Standard opioid conversion tables do not reliably apply, and clinical decision-making should involve a multidisciplinary approach including pain medicine or palliative care specialists and clinical pharmacy.
Administration and Monitoring
Methadone may be administered intravenously (slow IV push or infusion per institutional protocol) or orally. Given its prolonged and unpredictable half-life, accumulation and delayed respiratory depression are significant concerns, particularly during the first several days of therapy or following dose adjustments. Baseline and periodic ECG monitoring for QTc prolongation is recommended. Concomitant use of other QT-prolonging agents should be evaluated carefully.
- Monitor respiratory rate, sedation level, and oxygen saturation closely, especially within the first 24–72 hours of initiation or dose changes.
- Assess pain scores and adjust dosing only in consultation with pain service or pharmacy.
- Be aware of drug interactions, including CYP3A4 and CYP2D6 inhibitors/inducers, which can significantly alter methadone plasma levels.
- Consult institutional protocol for maximum dose guidance, as none is specified in the source description.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.